Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Identifieur interne : 004334 ( Ncbi/Curation ); précédent : 004333; suivant : 004335Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Auteurs : Mark S. Sulkowski [États-Unis] ; Walford J. Fessel [États-Unis] ; Adriano Lazzarin [Italie] ; Juan Berenguer [Espagne] ; Natalia Zakharova [Russie] ; Hugo Cheinquer [Brésil] ; Pierre Côté [Canada] ; Douglas Dieterich [États-Unis] ; Adrian Gadano [Argentine] ; Gail Matthews [Australie] ; Jean-Michel Molina [France] ; Christophe Moreno [Belgique] ; Juan Antonio Pineda [Espagne] ; Federico Pulido [Espagne] ; Antonio Rivero [Espagne] ; Jurgen Rockstroh [Allemagne] ; Dennis Hernandez [États-Unis] ; Fiona Mcphee [États-Unis] ; Timothy Eley [États-Unis] ; Zhaohui Liu [États-Unis] ; Patricia Mendez [États-Unis] ; Eric Hughes [États-Unis] ; Stephanie Noviello [États-Unis] ; Peter Ackerman [États-Unis]Source :
- Hepatology international [ 1936-0541 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association de médicaments, Co-infection (traitement médicamenteux), Co-infection (virologie), Femelle, Hepacivirus (), Hepacivirus (génétique), Humains, Hépatite C chronique (), Hépatite C chronique (traitement médicamenteux), Imidazoles (administration et posologie), Imidazoles (effets indésirables), Imidazoles (usage thérapeutique), Infections à VIH (), Infections à VIH (traitement médicamenteux), Interféron alpha (administration et posologie), Interféron alpha (effets indésirables), Interféron alpha (usage thérapeutique), Jeune adulte, Mâle, Polyéthylène glycols (administration et posologie), Polyéthylène glycols (effets indésirables), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (administration et posologie), Protéines recombinantes (effets indésirables), Protéines recombinantes (usage thérapeutique), Ribavirine (administration et posologie), Ribavirine (usage thérapeutique), Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Antiviraux, Imidazoles, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- effets indésirables : Antiviraux, Imidazoles, Interféron alpha, Polyéthylène glycols, Protéines recombinantes.
- génétique : Hepacivirus.
- traitement médicamenteux : Co-infection, Hépatite C chronique, Infections à VIH.
- usage thérapeutique : Antiviraux, Imidazoles, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- virologie : Co-infection.
- Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Hepacivirus, Humains, Hépatite C chronique, Infections à VIH, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Coinfection (drug therapy), Coinfection (virology), Drug Therapy, Combination, Female, HIV Infections (complications), HIV Infections (drug therapy), Hepacivirus (drug effects), Hepacivirus (genetics), Hepatitis C, Chronic (complications), Hepatitis C, Chronic (drug therapy), Humans, Imidazoles (administration & dosage), Imidazoles (adverse effects), Imidazoles (therapeutic use), Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Male, Middle Aged, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Polyethylene Glycols (therapeutic use), Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Ribavirin (administration & dosage), Ribavirin (therapeutic use), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Imidazoles, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Antiviral Agents, Imidazoles, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins.
- chemical , therapeutic use : Antiviral Agents, Imidazoles, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- complications : HIV Infections, Hepatitis C, Chronic.
- drug effects : Hepacivirus.
- drug therapy : Coinfection, HIV Infections, Hepatitis C, Chronic.
- genetics : Hepacivirus.
- virology : Coinfection.
- Adult, Aged, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.
DOI: 10.1007/s12072-017-9788-z
PubMed: 28210927
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001019
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001016
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001016
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004334
Links to Exploration step
pubmed:28210927Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.</title><author><name sortKey="Sulkowski, Mark S" sort="Sulkowski, Mark S" uniqKey="Sulkowski M" first="Mark S" last="Sulkowski">Mark S. Sulkowski</name><affiliation wicri:level="2"><nlm:affiliation>Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine , Baltimore, MD, USA. msulkowski@jhmi.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine , Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fessel, Walford J" sort="Fessel, Walford J" uniqKey="Fessel W" first="Walford J" last="Fessel">Walford J. Fessel</name><affiliation wicri:level="2"><nlm:affiliation>Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Kaiser Permanente San Francisco Medical Center, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lazzarin, Adriano" sort="Lazzarin, Adriano" uniqKey="Lazzarin A" first="Adriano" last="Lazzarin">Adriano Lazzarin</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Berenguer, Juan" sort="Berenguer, Juan" uniqKey="Berenguer J" first="Juan" last="Berenguer">Juan Berenguer</name><affiliation wicri:level="3"><nlm:affiliation>Unidad de Enfermedades Infecciosas/VIH (4100), Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas/VIH (4100), Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name><affiliation wicri:level="1"><nlm:affiliation>St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Cheinquer, Hugo" sort="Cheinquer, Hugo" uniqKey="Cheinquer H" first="Hugo" last="Cheinquer">Hugo Cheinquer</name><affiliation wicri:level="1"><nlm:affiliation>Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre, Porto Alegre, Rio Grande Do Sul</wicri:regionArea><wicri:noRegion>Rio Grande Do Sul</wicri:noRegion></affiliation></author><author><name sortKey="Cote, Pierre" sort="Cote, Pierre" uniqKey="Cote P" first="Pierre" last="Côté">Pierre Côté</name><affiliation wicri:level="1"><nlm:affiliation>Clinique Medicale Du Quartier Latin, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Clinique Medicale Du Quartier Latin, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Dieterich, Douglas" sort="Dieterich, Douglas" uniqKey="Dieterich D" first="Douglas" last="Dieterich">Douglas Dieterich</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Liver Disease, Mount Sinai School of Medicine, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Liver Disease, Mount Sinai School of Medicine, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gadano, Adrian" sort="Gadano, Adrian" uniqKey="Gadano A" first="Adrian" last="Gadano">Adrian Gadano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Italiano De Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Hospital Italiano De Buenos Aires, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Matthews, Gail" sort="Matthews, Gail" uniqKey="Matthews G" first="Gail" last="Matthews">Gail Matthews</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital (NSW), Darlinghurst, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital (NSW), Darlinghurst, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation wicri:level="3"><nlm:affiliation>Hopital Saint Louis, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hopital Saint Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Erasme, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hospital Erasme, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Pineda, Juan Antonio" sort="Pineda, Juan Antonio" uniqKey="Pineda J" first="Juan Antonio" last="Pineda">Juan Antonio Pineda</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Pulido, Federico" sort="Pulido, Federico" uniqKey="Pulido F" first="Federico" last="Pulido">Federico Pulido</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 De Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario 12 De Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Reina Sofia, Cordoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Reina Sofia, Cordoba</wicri:regionArea><wicri:noRegion>Cordoba</wicri:noRegion></affiliation></author><author><name sortKey="Rockstroh, Jurgen" sort="Rockstroh, Jurgen" uniqKey="Rockstroh J" first="Jurgen" last="Rockstroh">Jurgen Rockstroh</name><affiliation wicri:level="3"><nlm:affiliation>Universitaetsklinikum Bonn, Medizinische Klinik, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitaetsklinikum Bonn, Medizinische Klinik, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Hernandez, Dennis" sort="Hernandez, Dennis" uniqKey="Hernandez D" first="Dennis" last="Hernandez">Dennis Hernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mcphee, Fiona" sort="Mcphee, Fiona" uniqKey="Mcphee F" first="Fiona" last="Mcphee">Fiona Mcphee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Eley, Timothy" sort="Eley, Timothy" uniqKey="Eley T" first="Timothy" last="Eley">Timothy Eley</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Liu, Zhaohui" sort="Liu, Zhaohui" uniqKey="Liu Z" first="Zhaohui" last="Liu">Zhaohui Liu</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Hopewell, Pennington, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Hopewell, Pennington, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mendez, Patricia" sort="Mendez, Patricia" uniqKey="Mendez P" first="Patricia" last="Mendez">Patricia Mendez</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Hughes, Eric" sort="Hughes, Eric" uniqKey="Hughes E" first="Eric" last="Hughes">Eric Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Lawrenceville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Noviello, Stephanie" sort="Noviello, Stephanie" uniqKey="Noviello S" first="Stephanie" last="Noviello">Stephanie Noviello</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Lawrenceville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ackerman, Peter" sort="Ackerman, Peter" uniqKey="Ackerman P" first="Peter" last="Ackerman">Peter Ackerman</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28210927</idno><idno type="pmid">28210927</idno><idno type="doi">10.1007/s12072-017-9788-z</idno><idno type="wicri:Area/PubMed/Corpus">001019</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001019</idno><idno type="wicri:Area/PubMed/Curation">001016</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001016</idno><idno type="wicri:Area/PubMed/Checkpoint">001016</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001016</idno><idno type="wicri:Area/Ncbi/Merge">004334</idno><idno type="wicri:Area/Ncbi/Curation">004334</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.</title><author><name sortKey="Sulkowski, Mark S" sort="Sulkowski, Mark S" uniqKey="Sulkowski M" first="Mark S" last="Sulkowski">Mark S. Sulkowski</name><affiliation wicri:level="2"><nlm:affiliation>Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine , Baltimore, MD, USA. msulkowski@jhmi.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine , Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fessel, Walford J" sort="Fessel, Walford J" uniqKey="Fessel W" first="Walford J" last="Fessel">Walford J. Fessel</name><affiliation wicri:level="2"><nlm:affiliation>Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Kaiser Permanente San Francisco Medical Center, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lazzarin, Adriano" sort="Lazzarin, Adriano" uniqKey="Lazzarin A" first="Adriano" last="Lazzarin">Adriano Lazzarin</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Berenguer, Juan" sort="Berenguer, Juan" uniqKey="Berenguer J" first="Juan" last="Berenguer">Juan Berenguer</name><affiliation wicri:level="3"><nlm:affiliation>Unidad de Enfermedades Infecciosas/VIH (4100), Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas/VIH (4100), Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name><affiliation wicri:level="1"><nlm:affiliation>St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Cheinquer, Hugo" sort="Cheinquer, Hugo" uniqKey="Cheinquer H" first="Hugo" last="Cheinquer">Hugo Cheinquer</name><affiliation wicri:level="1"><nlm:affiliation>Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre, Porto Alegre, Rio Grande Do Sul</wicri:regionArea><wicri:noRegion>Rio Grande Do Sul</wicri:noRegion></affiliation></author><author><name sortKey="Cote, Pierre" sort="Cote, Pierre" uniqKey="Cote P" first="Pierre" last="Côté">Pierre Côté</name><affiliation wicri:level="1"><nlm:affiliation>Clinique Medicale Du Quartier Latin, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Clinique Medicale Du Quartier Latin, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Dieterich, Douglas" sort="Dieterich, Douglas" uniqKey="Dieterich D" first="Douglas" last="Dieterich">Douglas Dieterich</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Liver Disease, Mount Sinai School of Medicine, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Liver Disease, Mount Sinai School of Medicine, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gadano, Adrian" sort="Gadano, Adrian" uniqKey="Gadano A" first="Adrian" last="Gadano">Adrian Gadano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Italiano De Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Hospital Italiano De Buenos Aires, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Matthews, Gail" sort="Matthews, Gail" uniqKey="Matthews G" first="Gail" last="Matthews">Gail Matthews</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital (NSW), Darlinghurst, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital (NSW), Darlinghurst, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation wicri:level="3"><nlm:affiliation>Hopital Saint Louis, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hopital Saint Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Erasme, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hospital Erasme, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Pineda, Juan Antonio" sort="Pineda, Juan Antonio" uniqKey="Pineda J" first="Juan Antonio" last="Pineda">Juan Antonio Pineda</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Pulido, Federico" sort="Pulido, Federico" uniqKey="Pulido F" first="Federico" last="Pulido">Federico Pulido</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 De Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario 12 De Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Reina Sofia, Cordoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Reina Sofia, Cordoba</wicri:regionArea><wicri:noRegion>Cordoba</wicri:noRegion></affiliation></author><author><name sortKey="Rockstroh, Jurgen" sort="Rockstroh, Jurgen" uniqKey="Rockstroh J" first="Jurgen" last="Rockstroh">Jurgen Rockstroh</name><affiliation wicri:level="3"><nlm:affiliation>Universitaetsklinikum Bonn, Medizinische Klinik, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitaetsklinikum Bonn, Medizinische Klinik, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Hernandez, Dennis" sort="Hernandez, Dennis" uniqKey="Hernandez D" first="Dennis" last="Hernandez">Dennis Hernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mcphee, Fiona" sort="Mcphee, Fiona" uniqKey="Mcphee F" first="Fiona" last="Mcphee">Fiona Mcphee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Eley, Timothy" sort="Eley, Timothy" uniqKey="Eley T" first="Timothy" last="Eley">Timothy Eley</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Liu, Zhaohui" sort="Liu, Zhaohui" uniqKey="Liu Z" first="Zhaohui" last="Liu">Zhaohui Liu</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Hopewell, Pennington, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Hopewell, Pennington, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mendez, Patricia" sort="Mendez, Patricia" uniqKey="Mendez P" first="Patricia" last="Mendez">Patricia Mendez</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Hughes, Eric" sort="Hughes, Eric" uniqKey="Hughes E" first="Eric" last="Hughes">Eric Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Lawrenceville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Noviello, Stephanie" sort="Noviello, Stephanie" uniqKey="Noviello S" first="Stephanie" last="Noviello">Stephanie Noviello</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Lawrenceville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ackerman, Peter" sort="Ackerman, Peter" uniqKey="Ackerman P" first="Peter" last="Ackerman">Peter Ackerman</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Wallingford, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><series><title level="j">Hepatology international</title><idno type="eISSN">1936-0541</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Coinfection (drug therapy)</term><term>Coinfection (virology)</term><term>Drug Therapy, Combination</term><term>Female</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C, Chronic (complications)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Imidazoles (adverse effects)</term><term>Imidazoles (therapeutic use)</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (therapeutic use)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Co-infection (traitement médicamenteux)</term><term>Co-infection (virologie)</term><term>Femelle</term><term>Hepacivirus ()</term><term>Hepacivirus (génétique)</term><term>Humains</term><term>Hépatite C chronique ()</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Imidazoles (administration et posologie)</term><term>Imidazoles (effets indésirables)</term><term>Imidazoles (usage thérapeutique)</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (effets indésirables)</term><term>Interféron alpha (usage thérapeutique)</term><term>Jeune adulte</term><term>Mâle</term><term>Polyéthylène glycols (administration et posologie)</term><term>Polyéthylène glycols (effets indésirables)</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (administration et posologie)</term><term>Protéines recombinantes (effets indésirables)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Ribavirine (administration et posologie)</term><term>Ribavirine (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Imidazoles</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Imidazoles</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Imidazoles</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Imidazoles</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Imidazoles</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term><term>Hépatite C chronique</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Imidazoles</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Co-infection</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coinfection</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Hepacivirus</term><term>Humains</term><term>Hépatite C chronique</term><term>Infections à VIH</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004334 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004334 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:28210927
|texte= Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:28210927" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |